Arontier is an AI drug discovery company specializing in protein structure-based design. Its AI integrates structural biology and physics-based energy modeling to optimize drug candidates across modalities including small molecules, proteins, peptides, antibodies, and vaccine antigens.

Arontier accelerates early-stage drug discovery through structure-based AI design, reducing time for candidate discovery and optimization. With experience in small molecules, antibodies, peptides, and proteins, it provides tailored solutions from hit discovery to lead optimization.